2024
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2)
Wharton S, le Roux C, Kosiborod M, Platz E, Brueckmann M, Jastreboff A, Hussain S, Pedersen S, Borowska L, Unseld A, Kloer I, Kaplan L, committees and investigators T. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™‐1 and ‐2). Obesity 2024 PMID: 39495965, DOI: 10.1002/oby.24184.Peer-Reviewed Original ResearchTreatment of obesityBaseline BMIRandomized phase 3 clinical trialOnce-weekly subcutaneous injectionsPhase 3 clinical trialsBaseline to weekDouble-blind trialObesity-related complicationsBody weight reductionAbsence of T2DSystolic blood pressureLiver fat contentType 2 diabetesMagnetic resonance imagingMeasures of glycemiaSecondary endpointsDosing flexibilityProportion of participantsLifestyle modificationInvestigated glucagonSubcutaneous injectionBlood pressureBody compositionResonance imagingObesity
2010
Body Mass Index, Metabolic Factors, and Striatal Activation During Stressful and Neutral-Relaxing States: An fMRI Study
Jastreboff AM, Potenza MN, Lacadie C, Hong KA, Sherwin RS, Sinha R. Body Mass Index, Metabolic Factors, and Striatal Activation During Stressful and Neutral-Relaxing States: An fMRI Study. Neuropsychopharmacology 2010, 36: 627-637. PMID: 21048702, PMCID: PMC3055687, DOI: 10.1038/npp.2010.194.Peer-Reviewed Original ResearchConceptsMetabolic factorsFunctional magnetic resonance imagingOB individualsOW/OB individualsVentral striatumVS activationBody mass index statusCortico-limbic regionsNon-homeostatic feedingBody mass indexNormal-weight individualsMagnetic resonance imagingAlcohol cue exposureMass indexObese individualsPlasma glucoseStriatal dysfunctionWeight individualsIndex statusPersonalized stressResonance imagingSignificant associationNW individualsCue exposureMetabolic changes